Damora Therapeutics (DMRA) Current Assets (2019 - 2026)

Damora Therapeutics (DMRA) has 8 years of Current Assets data on file, last reported at $535.4 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 3493.34% year-over-year to $535.4 million; the trailing twelve-month figure through Mar 2026 stood at $535.4 million (up 3493.34% YoY), and the FY2025 full-year result was $260.4 million, up 1446.41% from the prior year.
• Current Assets for Q1 2026 stood at $535.4 million, up from $260.4 million in the prior quarter.
• Across five years, Current Assets topped out at $535.4 million in Q1 2026 and bottomed at $9.8 million in Q3 2025.
• The 5-year median for Current Assets is $47.1 million (2023), against an average of $84.6 million.
• The widest annual swing landed in 2024, when Current Assets tumbled 54.99%; it then surged 3493.34% in 2026.
• A 5-year view of Current Assets shows it stood at $63.9 million in 2022, then tumbled by 42.45% to $36.8 million in 2023, then slumped by 54.21% to $16.8 million in 2024, then soared by 1446.41% to $260.4 million in 2025, then surged by 105.61% to $535.4 million in 2026.
• The last three Current Assets figures came in at $535.4 million (Q1 2026), $260.4 million (Q4 2025), and $9.8 million (Q3 2025), per Business Quant data.

Peer Comparison